DeciBio
Carl Schoellhammer is an Associate Partner at DeciBio, specializing in management consulting within growth strategy, mergers and acquisitions, and biopharma pipeline prioritization across the healthcare and life science sectors. Additionally, Carl serves as Managing Director at DeciBio BroadOak BioTools Venture Fund, focusing on investments in life science technologies to advance precision medicine. As the founding CEO and Director of Suono Bio, Carl has led the development of innovative therapeutic products utilizing ultra-rapid delivery technology for inflammatory-mediated diseases. Academic qualifications include a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology, where Carl also completed postdoctoral research. Prior experience includes roles at Merck, Flagship Ventures, and leadership in the MIT $100K Entrepreneurship Competition.
DeciBio
1 followers
DeciBio Consulting is a boutique strategy consulting firm focusing on the life science industry. DeciBio's mission is to provide the strategic insights that accelerate the development, adoption, and accessibility of personalized medicine. Headquartered in Los Angeles, CA, DeciBio serves clients and customers across the globe, ranging from incubator-stage startups to Fortune 500 life science corporations. DeciBio addresses business solutions that range from market landscape analyses to full commercial strategies, including organic and inorganic growth opportunities (commercial due diligences). DeciBio’s work is typically supported by a mix of primary and secondary research leveraging Dexter, its in-house expert network, and DeciBio Analytics’ proprietary data intelligence products. DeciBio’s Analytics division offers numerous data products to support strategic insights, including in clinical diagnostics (the DxBooks), immuno-oncology (the I/O BioMAP), omics market segmentation (the MarketBooks), and the entire life sciences industry (BioTrack). Internal teams such as the Culture Committee, Women* in Consulting, and Gays in Consulting enrich the employee experience. DeciBio’s Social Impact board and the DeciBio Impact Lab work collaboratively across divisions and externally to uproot discrimination and increase access to precision medicine.